Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Curr Opin Immunol. 2016 Apr;39:90-5. doi: 10.1016/j.coi.2016.01.004. Epub 2016 Jan 30.
Adoptive cell therapy (ACT) by infusion of autologous or redirected tumor-specific T-cells has had a major impact on the treatment of several metastasized malignancies that were until now hardly treatable. Recent findings provide a more profound knowledge on the underlying mechanisms of success and allow the optimization of the ACT protocol with respect to (1) the treatment related side-effects, (2) the quality and specificity of infused T-cells, and (3) the immunosuppressive phenotype of the tumor environment. In this review, the results and insights in the success of ACT as well as the possibilities to improve ACT and its exploitation as treatment option for various metastatic cancer types, will be discussed.
过继性细胞疗法（ACT）通过输注自体或重定向的肿瘤特异性 T 细胞，对治疗几种转移性恶性肿瘤产生了重大影响，而这些肿瘤在以前是几乎无法治疗的。最近的研究结果提供了对成功的潜在机制的更深入了解，并允许优化 ACT 方案，具体涉及：（1）与治疗相关的副作用；（2）输注 T 细胞的质量和特异性；以及（3）肿瘤环境的免疫抑制表型。在这篇综述中，将讨论 ACT 成功的结果和见解，以及改善 ACT 及其作为各种转移性癌症类型的治疗选择的利用的可能性。
